ZBIO Stock Forecast & Price Target
ZBIO Analyst Ratings
Bulls say
Zenas BioPharma Inc is strategically positioned to capture a significant share of the estimated $3 billion market opportunity in IgG4-RD, showcasing the potential for robust revenue growth from its proprietary treatment, obexelimab. With approximately $350 million on its balance sheet, the company is well-capitalized to support ongoing clinical trials and navigate multiple upcoming catalyst events anticipated over the next 18 months. Additionally, the differentiated mechanism of action of obexelimab, particularly its dual engagement of CD19 and FcγRIIb, may offer unique advantages in treating autoimmune conditions, thereby enhancing its competitive positioning in the biopharmaceutical landscape.
Bears say
Zenas BioPharma reported a net loss of $52.6 million for the fourth quarter of 2024 and a total yearly loss of $157 million, indicating significant financial strain as it continues its clinical development phase. The company's market position remains precarious due to potential risks, including the possibility that its product candidate obexelimab may fail to meet expected commercial revenue targets, alongside challenges in securing necessary funding to sustain operations. Furthermore, with the stock trading below its cash reserves, Zenas BioPharma faces heightened concerns regarding its ability to compete effectively amid emerging competitors and ongoing R&D setbacks.
This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ZBIO Analyst Forecast & Price Prediction
Start investing in ZBIO
Order type
Buy in
Order amount
Est. shares
0 shares